About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Highlights from today's RNS


Significant 50% reduction in tumour volume

'A reduction in tumour volume of 50% is seen by the National Cancer Institute in
America, and other leading authorities as being highly significant'

The mice did not show any toxic or side effects, such as
weight loss, associated with compound administration. This suggests that the
compound is highly selective for the tumour, unlike the more traditional cancers
therapies, where effectiveness can be limited due to associated toxicities.

Professor Tom Cotter, founder and CSO of EiRx. 'We are now in active
discussions with a developmental company to further develop this molecule and to
prepare it for a future phase 1 clinical trial.

With an estimated 112,000 dying from the disease.
The incidence is forecast to increase annually at an average rate of 3%. The size
of the market for breast cancer drugs is $6.2 billion; representing 17% of the
total spend of the cancer market.

hello driver

plm2349
Hi, are you still on these.

there is more news on thursday.. I reckon it will be better than todays news

driver of course!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

PH
Thanks Cannoncan.

A nice 23% up with steady buying today thats OK by me, better than pump and dump. Onwards and upwards tomorrow.

Hi Driver

not a bad day, thanks for the early post, have just got in, do you think theres more to come, Iam still holding at the moment : )

smiler
Yes the RNS looked very promising for a company with such a small M/Cap the volume of trades today says theres a lot of interest and new awareness for the stock they also have other compounds and future drugs in the pipe line. This is definitely a long-term hold we could see 10p one day IMO.

Thanks driver, could be interesting , happy to sit and wait now in a small profit : )

EIRX THERAPEUTICS PLC
('EiRx' or 'the Company')

500,000 PLACING
http://moneyam.uk-wire.com/cgi-bin/articles/200609201526072396J.html

Driver

That was some buy 25 mill, just before closing.

smiler
That was a B trade yesterday, nice bit of volume this morning though and the sp moving up.
It's interesting that Seymour Pierce Ellis took on the new shares instead of Hoodless Brennan & Partners. They may be there new house broker but no announcement as yet.

Thanks for that, ref the mail I sent you they have changed today : )

smiler
Cheers on my watch list.

As we thought.

EIRX THERAPEUTICS PLC

('EiRx' or 'the Company')
CHANGE OF BROKER

Cork, Ireland - EiRx Therapeutics plc (AIM: ERX), the drug discovery company
developing targeted therapies for cancer, is pleased to announce that it has
appointed Seymour Pierce Ellis as its sole broker with immediate effect.

more news next week guys, I am hopeing its the news on colonical cancer

OK PH will be watching, where have you been, on holiday ??

Any thing above 28 today was a buy so the trades look a bit distorted it would be foolish to sell with further news in the pipeline unless you need the money that is.

Driver

Strange, I keep watching this share more than the others, could make some good money on this 1p would be a good start ! : )